Skip to content
Frontiers
Search

Correction

Frontiers in Oncology ·

Volume 16 - 2026 | https://doi.org/10.3389/fonc.2026.2013767

Correction: Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications

  • Frontiers Production Office1*corresponding author
  1. Frontiers Media SA, Lausanne, Switzerland
Article metrics0 viewsView details
PDFCiteMetrics

Abstract

Keywords

There was an error in Figure 4 as published. The image displayed as Figure 4 is Supplementary Figure 2, which was wrongly published in place of Figure 4. The caption of the published Figure 4 was correct and does not need to be changed. The corrected Figure 4 appears below.

Gene-level associations between mutation status and 24-month overall survival in the North Swedish and world lung cancer cohorts. **(A, B)** show volcano plots for the North Swedish cohort (n=528) and the survival-linked world cohort (n=2,197), respectively. Each point represents one gene analyzed at the patient level. For each gene, patients with at least one mutation in that gene were compared with all other patients without that gene mutation. The x-axis shows the difference in Kaplan-Meier estimated 24-month overall survival probability (mutated minus non-mutated), and the y-axis shows -log10(p) from the two-sided log-rank test. Only genes mutated in at least 5 patients were included. Point size reflects the number of mutated patients, and genes with p < 0.05 are highlighted. **(C, D)** Forest plots illustrating 24-month survival probabilities for patients with mutations in selected genes. **(C)** compares the difference in 24-month survival probability for each gene between the North Swedish cohort (blue) and the rest of the world (yellow). Genes are shown on the y-axis, with the x-axis representing the difference in survival probability at 24 months. Dots represent the survival probability for each cohort, and horizontal lines connect the two cohorts for each gene. Significance stars (*, **, ***) indicate statistical significance of the difference in survival probability (p < 0.05, p < 0.01, p < 0.001, respectively). **(D)** shows the 24-month survival probability for the Swedish cohort, stratified by stage group (Stage 1-2: blue; Stage 3-4: orange). The number above each dot indicates the number of unique patients in each gene/stage, and horizontal lines connect the two stage groups for each gene.
Figure 1. Gene-level associations between mutation status and 24-month overall survival in the North Swedish and world lung cancer cohorts. (A, B) show volcano plots for the North Swedish cohort (n=528) and the survival-linked world cohort (n=2,197), respectively. Each point represents one gene analyzed at the patient level. For each gene, patients with at least one mutation in that gene were compared with all other patients without that gene mutation. The x-axis shows the difference in Kaplan-Meier estimated 24-month overall survival probability (mutated minus non-mutated), and the y-axis shows -log10(p) from the two-sided log-rank test. Only genes mutated in at least 5 patients were included. Point size reflects the number of mutated patients, and genes with p < 0.05 are highlighted. (C, D) Forest plots illustrating 24-month survival probabilities for patients with mutations in selected genes. (C) compares the difference in 24-month survival probability for each gene between the North Swedish cohort (blue) and the rest of the world (yellow). Genes are shown on the y-axis, with the x-axis representing the difference in survival probability at 24 months. Dots represent the survival probability for each cohort, and horizontal lines connect the two cohorts for each gene. Significance stars (*, , *) indicate statistical significance of the difference in survival probability (p < 0.05, p < 0.01, p < 0.001, respectively). (D) shows the 24-month survival probability for the Swedish cohort, stratified by stage group (Stage 1-2: blue; Stage 3-4: orange). The number above each dot indicates the number of unique patients in each gene/stage, and horizontal lines connect the two stage groups for each gene.

Supplementary Figure 3, which is cited in the Results section, was erroneously omitted from the Supplementary Material as published. The Supplementary Material has been updated to include Supplementary Figure 3.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Citation

Office, F. P. (2026). Correction: Real world genomic profiling in non-small cell lung cancer reveals regional variations with clinical implications. Frontiers in Oncology, Volume 16. https://doi.org/
Received
Accepted
Published
Volume
16 - 2026

Copyright

Copyright © 2026 Frontiers Production Office.

License: https://creativecommons.org/licenses/by/4.0/

*Correspondence: Frontiers Production Office

Article metrics

Views
0
Downloads
0
Citations
0
Shares
0

Related articles

Hypothesis and TheoryInfluencing the exposome, patient macroenvironment, tumor microenvironment through-line to improve clinical outcomesSamuel F. Yanuck, Neil E. AlexisSystematic ReviewChinese medicine combined with EGFR-TKIs in EGFR-mutated advanced NSCLC: a meta-analysis of efficacy and safetyXiaohong Li, Die Qian, Shuai Liu, Mingmin Na, Bihong Dai, Chunping WanOriginal ResearchAge-stratified survival and competing mortality in adult acute lymphoblastic leukemia and lymphoblastic lymphoma: a population-based competing-risk and restricted mean survival analysisZhe Li, Jianglin Yu